Abstract

Animal lung macrophages or human peripheral blood mononuclear cells have been used for testing intracellular activity of anti- Legionella antibiotics; such studies are labor intensive such that comparative antibiotic studies for the many Legionella species are few. We evaluated a human monocyte cell line (HL-60) as an alternative model. HL-60 (1.5 × 10 6 cells/well) was differentiated into adherent cells and infected with 1.5 × 10 7 CFU of Legionella pneumophila ( L. pneumophila). Erythromycin and quinolones, ciprofloxacin, ofloxacin, and levofloxacin were added to cells at 1 and 8× MIC. Percent (%) inhibition ratios equal to total L. pneumophila with agent divided by L. pneumophila without agent × 100 were determined at 48 h; lower ratios implied greater potency. By broth dilution in buffered yeast extract broth, the most potent agents against L. pneumophila were (MIC): ciprofloxacin (0.015–0.03), ofloxacin (0.015–0.03), levofloxacin (0.015–0.03), erythromycin (0.125–1.0 μg/mL). In the intracellular model, the most potent inhibitors of L. pneumophila multiplication at 8× MIC were (in order of potency) levofloxacin (24.2%), ciprofloxacin (30.6%), ofloxacin (37.1%), and erythromycin (55.0%). All the quinolones were highly active and significantly more potent against L. micdadei and L. bozemanii when compared to L. pneumophila.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call